Hussam Eltoukhy
Hematology · West Long Branch, NJNPI 1356737324
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $901, more than ten times the $14 reported in 2022. That places this record below the midpoint for hematology clinicians in NJ, where the typical reported total is $2,217.
Across 114 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$371
- Pfizer$218
- Bristol Myers Squibb$175
- ADC Therapeutics America, Inc.$114
- Bayer$113
- Taiho Oncology, Inc.$113
- plus $972 from 22 others
What the payments were for
- Food & beverage$2,01697%
- Education$593%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 22 | $371 |
| Pfizer | 16 | $218 |
| Bristol Myers Squibb | 11 | $175 |
| ADC Therapeutics America, Inc. | 2 | $114 |
| Bayer | 4 | $113 |
| Taiho Oncology, Inc. | 6 | $113 |
| Astellas Pharma US Inc | 5 | $88 |
| AstraZeneca(2 entities) | 5 | $87 |
| GSK | 4 | $85 |
| Gilead(2 entities) | 5 | $81 |
| Shield Therapeutics Inc | 1 | $79 |
| Mirati Therapeutics, Inc. | 4 | $67 |
| Incyte Corporation | 4 | $66 |
| Novartis | 3 | $64 |
| AbbVie | 4 | $57 |
| Tempus AI, Inc | 3 | $44 |
| Adaptive Biotechnologies Corporation | 2 | $39 |
| Exelixis Inc. | 2 | $36 |
| Array Biopharma Inc | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Genmab U.S., Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
| Pharmaessentia USA Corporation | 1 | $14 |
| Pharmacosmos Therapeutics Inc. | 1 | $14 |
| Blueprint Medicines Corporation | 1 | $13 |
How this compares
$2,075 in reported general payments places this provider in the 45th percentile of 43 hematology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 39 | $518,027 |
| JakafiRuxolitinib Phosphate | 16 | $341,095 |
| ImbruvicaIbrutinib | 17 | $273,828 |
| PomalystPomalidomide | 12 | $265,680 |
| VenclextaVenetoclax | 49 | $255,821 |
| RevlimidLenalidomide | 20 | $245,776 |
| SprycelDasatinib | 12 | $214,161 |
| BrukinsaZanubrutinib | 15 | $202,043 |
| NinlaroIxazomib Citrate | 14 | $174,711 |
| BesremiRopeginterferon Alfa-2b-Njft | 12 | $101,337 |
| EliquisApixaban | 38 | $31,250 |
| XareltoRivaroxaban | 25 | $14,376 |
| Azacitidine | 49 | $3,124 |
| Acyclovir | 134 | $2,173 |
| Hydroxyurea | 37 | $1,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $17 | $479,84124 claims |
| Incyte CorporationJakafi | $66 | $341,09516 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $15 | $273,82817 claims |
| AbbVieVenclexta | $57 | $255,82149 claims |
| Bristol Myers SquibbRevlimid | $175 | $245,77620 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $21 | $174,71114 claims |
| Pharmaessentia USA CorporationBesremi | $14 | $101,33712 claims |
| PfizerEliquis | $218 | $31,25038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 43 hematology providers in New Jersey.
Other hematology in West Long Branch
- Patrick LeeWest Long Branch$2K
- Ahmed GalalMorristown$1.7M
- Mansi ShahNew Brunswick$131K
- Fermina MazzellaNewark$49K
- Muhammad AbbasiMountain Lakes$22K
- Robert TassanWestwood$21K
- Marcus CarrNorth Brunswick$19K
- Jason LevitzMountain Lakes$19K
- Christopher TullyMountain Lakes$17K
- Claire PhilippNew Brunswick$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.